Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2024 | Prognostic Value of MRR in STEMI: Group Analysis of Individual Patients

Despite primary angioplasty, many patients with ST elevation acute myocardial infarction with (STEMI) show evidence of microvascular dysfunction. This dysfunction can be characterized by two main factors:

  1. Minimal microvascular resistance, evaluated with index of microvascular resistance (IMR).
  2. Microcirculation vasodilatory capacity– measured with coronary flow reserve (CFR) – which might be influenced by epicardial disease.
EuroPCR 2024

A new specific index has recently been identified to assess microcirculation called microvascular resistance reserve (MRR), which allows measuring vasodilatory capacity independent of the epicardium. 

The purpose of this study was to determine the prognostic value of MRR in clinical outcomes of STEMI patients, and establish an optimal cutoff MRR value to predict adverse events. To this aim, the study looked at data of STEMI patients from six cohorts including a total 446 participants. Microvascular function was assessed independently after PCI using the bolus thermodilution technique to calculate MRR.

Included patients were mean 61.6 years, 82% were men, 42.4% smokers and 14.8% diabetic. Those with MRR ≤ 1.25 showed 67.5% of the combined end point of all-cause mortality or cardiac failure, vs. only 19.1% in those with MRR > 1.25 (HR 4.16, CI 95% 2.31-7.50).

Read also: EuroPCR 2024 | Influence and Effect of CAD Physiopathological Patterns in the Safety and Efficacy of PCI.

The authors concluded MRR is an independent factor to predict adverse events in STEMI patients, establishing a cutoff value of 1.25 for this index.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Mohamed El Farissi, at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...